SCHEMBL5887133

SCHEMBL5887133

COC(=O)c1ccc(CNC(=O)c2ccc(-n3c(=O)ccc4c(C)nc(Oc5ccc(C(C)=O)cc5)nc43)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPK14 Q16539 2/20 0.40
MAPK8 P45983 2/20 0.39
MAPK9 P45984 2/20 0.39
MAPK10 P53779 2/20 0.39
MMP13 P45452 2/20 0.39
MMP2 P08253 1/20 0.39
CYP3A4 P08684 1/20 0.39
STAT3 P40763 1/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 4/20 0.38
TP53 P04637 4/20 0.38
EPHX2 P34913 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
RXFP1 Q9HBX9 2/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886768 0.92 HPGD (0.47) SMN1; SMN2MEN1KMT2AMAPK14MMP13
SCHEMBL5886861 0.91 MAPK14 (0.40) SMN1; SMN2MEN1KMT2AMAPK14MAPK8
SCHEMBL5887053 0.91 MAPK14 (0.47) SMN1; SMN2MAPK14MAPK8MAPK9MAPK10
SCHEMBL5887029 0.90 MAPK14 (0.48) SMN1; SMN2MAPK14MMP13MMP2CYP3A4
SCHEMBL5887080 0.90 EPHX2 (0.42) SMN1; SMN2MAPK14MAPK8MAPK9MMP13
SCHEMBL5886992 0.89 RECQL (0.44) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
SCHEMBL5886839 0.86 MAPK14 (0.51) SMN1; SMN2MAPK14MMP13MMP2CYP3A4
SCHEMBL5887065 0.86 HTT (0.45) SMN1; SMN2MEN1KMT2AMAPK14MAPK8
SCHEMBL5886807 0.85 MAPK14 (0.46) SMN1; SMN2MAPK14MMP13MMP2CYP3A4
SCHEMBL5886905 0.84 RORC (0.41) SMN1; SMN2MEN1KMT2AMAPK14MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP SMN1; SMN2 2219/4885MEN1 2183/4885KMT2A 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.